Resmed (RMD) Osake Kurssi
Resmed Kurssi
Liikevaihto on kasvanut 11,5 % vuodessa viimeisten 19 vuoden aikana 5,65 Mrd. USD:een. Osakekohtainen tulos on kasvanut 18,4 % vuodessa viimeisten 19 vuoden aikana. Resmedn nettomarginaali on nyt 26,9 %, noussut 21,8 %:sta muutama vuosi sitten. Resmedn osinkotuotto on tällä hetkellä noin 1,06 %. Jakosuhde on noin 28 % tuloksesta. Osinko on kasvanut 15,0 % vuodessa viimeisten 14 vuoden aikana. Analyytikoiden mediaanitavoitehinta on 230,00 USD, eli yli nykyhintaa 1,8 %. 27 analyytikosta 13 suosittaa ostoa — kokonaiskonsensus on Pidä.
Resmed osakekurssi
Resmed liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Resmed -osakkeesta
Resmed Inc operates with a business model focused on the development and manufacturing of medical equipment for the management of sleep-disordered breathing and chronic respiratory diseases. The company's core products include devices for the treatment of sleep apnea, ventilators, and respiratory care solutions. Resmed Inc's business model emphasizes innovation and research to provide superior quality products to improve the lives of individuals suffering from these conditions. With a strong commitment to advancing respiratory healthcare, Resmed Inc has established itself as a leading global provider of sleep and respiratory medical devices and solutions.
Resmed Inc is primarily active in the industries of medical devices and sleep apnea solutions.
Resmed Inc faces competition from prominent companies in the market. Some of its main competitors include Philips Respironics, Fisher & Paykel Healthcare, and ResMed Ltd. These companies also specialize in providing solutions for sleep and respiratory disorders. Resmed Inc competes on various fronts in the market, including product innovation, quality, and customer service. Despite the competitive landscape, Resmed Inc has established itself as a leading player in the industry, offering cutting-edge products to improve sleep apnea and respiratory care.
ResMed Inc. is a leading global company that specializes in the development and manufacturing of innovative medical devices and solutions for the treatment of sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Founded in 1989, ResMed has evolved into a pioneer in sleep medicine, providing a wide range of products such as masks, devices, and software to improve respiratory health and enhance the quality of life for millions of patients worldwide. With a commitment to continuous innovation and cutting-edge technology, ResMed has established itself as a trusted and renowned name in the medical industry, dedicated to improving the well-being of individuals affected by respiratory disorders.
ResMed Inc has achieved significant milestones since its establishment. The company revolutionized the sleep apnea industry by introducing innovative and effective solutions for patients worldwide. ResMed pioneered the development of continuous positive airway pressure (CPAP) therapy, offering a breakthrough treatment method that significantly improved patient outcomes. Utilizing advanced technology and research, ResMed expanded its product line to include state-of-the-art sleep and respiratory care devices. The company's commitment to innovation and patient-centered solutions has led to numerous awards and recognitions, solidifying ResMed's position as a global leader in the sleep health industry. ResMed Inc continues to drive advancements in sleep apnea and respiratory care, improving the lives of millions.
Resmed Inc is primarily present in various countries and regions across the globe. The company has a strong presence in the United States, where its headquarters is located. It also operates and serves customers in Australia, Canada, France, Germany, Japan, and the United Kingdom. Additionally, Resmed Inc has expanded its reach to many other countries in Europe, Asia, and the Americas. With its global presence, Resmed Inc continues to provide innovative solutions and improve the well-being of individuals suffering from sleep apnea and other respiratory disorders.
Resmed Inc is a leading global medical technology company specializing in the development and manufacturing of innovative devices and solutions for sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. The company is dedicated to improving patients' quality of life by providing high-quality, patient-centric products and services. Resmed Inc's corporate philosophy centers around a commitment to innovation, excellence, and collaboration. By continuously investing in research and development, Resmed Inc aims to stay at the forefront of medical advancements and deliver effective and reliable solutions to the patients it serves.
Analyytikot asettavat tällä hetkellä Resmed-osakkeelle keskimääräisen tavoitehinnan 239,67 USD (mediaani: 230,00 USD), mikä merkitsee +6,1 % viimeisimpään hintaan verrattuna. Konsensus perustuu 27 analyytikkoarvioon.
27 analyytikkoa arvioi tällä hetkellä Resmed-osaketta: 13 suosittaa ostoa, 12 pitoa ja 2 myyntiä.
Nykyisellä valuuttakurssilla Resmed-osake noteerataan hintaan 201,79 EUR (225,98 USD).
Resmed-osake (RMD) on listattuna 10 pörssissä, muun muassa: NYSE (RMD), London (0KW4.L), SIX (Zürich) (RME.SW), Frankfurt (RME.F), München (RME.MU), Stuttgart (RME.SG), Düsseldorf (RME.DU), Berlin (RME.BE).
ResMed Inc. is a global company specialized in the development, manufacturing, and marketing of sleep apnea therapy products. Its business model is based on helping people around the world improve their sleep quality and promote their health. The company is divided into three main divisions: sleep and ventilation therapy, diagnostics, and software and services. The sleep and ventilation therapy division includes the production of ventilation devices, masks, and accessories that help keep the airway open during sleep and ensure optimal oxygen supply to the body. The diagnostics division offers solutions for detecting sleep disorders such as sleep apnea, including recording devices and software that can measure and analyze the patient's sleep behavior. The software and services division includes various solutions for medical professionals and patients to monitor and optimize therapy. ResMed Inc. is a pioneer in the industry and is considered an innovation leader in sleep apnea therapy. The company works closely with leading doctors and researchers to continuously develop new and improved products. ResMed Inc. also has a strong presence in the global market and operates in over 100 countries worldwide. One of ResMed Inc.'s most well-known products is the AirSense™ 10 AutoSet™, an intelligent ventilation device that automatically provides the patient with optimal respiratory support based on sensors and algorithms. The AirFit™ mask range from ResMed provides the patient with a comfortable and secure fit for successful therapy. ResMed Inc. also offers a variety of mobile apps that enable easy monitoring and management of the patient's therapy. ResMed Inc. also utilizes its industry-leading expertise to collaborate with other companies and organizations. For example, the company partners with medical device manufacturers and pharmaceutical companies to develop innovative solutions for the healthcare industry. ResMed Inc. has established itself as a trusted partner for medical professionals and patients. The company takes a holistic approach to sleep apnea therapy by engaging and educating patients and healthcare professionals. ResMed Inc. is always striving to improve the lives of patients with sleep apnea and provide them with a higher quality of life. Overall, ResMed Inc.'s business model is focused on the development and production of high-quality and innovative products for sleep apnea therapy. The company continually pursues new approaches to improve the quality of therapy for patients, always with the goal of promoting the health and well-being of its users.
liikevaihto Resmed on 5,65 Mrd. USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
voitto Resmed on 1,52 Mrd. USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Resmed:n hinta-voitto-suhde (P/E) on tällä hetkellä 21,51. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Resmed-osakkeen arvostusta.
Resmed:n hinta-myynti-suhde (P/S) on tällä hetkellä 5,79. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Resmed-osakkeen arvostuskennuslukuna.
Resmed:n Eulpool-laatuscore on 8/10.
Resmed:n ISIN on US7611521078. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Resmed:n WKN on 895878. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Resmed:n ticker on RMD. Tämä pörssinoteeraus käytetään Resmed-osakkeiden kauppaan pörssissä.
Resmed osake
Resmed vertaisryhmä
Resmed Ticker
Resmed FIGI
Kaikki tunnusluvut ja syvällinen analyysi Resmed:sta
Meidän osakeanalyysimme Resmed-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Resmed:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: